# US 2023/0066527 A1 · Therapeutic protein selection in simulated in vivo conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0066527 A1
- Document ID: US20230066527A1
- Status: Published application
- Kind: A1
- Application number: 17/892,618
- Filed: 2022-08-22
- Published: 2023-03-02
- Earliest claimed: 2018-08-13
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Dorothy Kim; Michael Marlow
- Web page: https://patentgrep.com/patent/US20230066527A1

## CPC

- G01N 33/54393: {Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding}
- G01N 33/6845: {Methods of identifying protein-protein interactions in protein mixtures}
- G01N 33/5306: {Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding}
- G01N 33/54306: {Solid-phase reaction mechanisms}
- G01N 33/6854: {Immunoglobulins}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A method of determining the effect of non-specific interactions in simulated in vivo conditions is presently disclosed. The method includes (a) contacting a solution comprising a biologically relevant molecular crowding agent and a target molecule with a biosensor, wherein the surface of the biosensor comprises a capture molecule that specifically binds the target molecule; (b) allowing the target molecule to bind to the capture molecule; and (c) determining an amount of the target molecule bound to capture molecule using biolayer interferometry.

## Claims

### Claim 1

A method of determining an effect of non-specific interactions on monoclonal antibody-antigen interactions in simulated blood conditions, comprising:
(a) contacting a solution comprising a blood protein and a monoclonal antibody with a biosensor, wherein a surface of the biosensor comprises an antigen that specifically binds to the monoclonal antibody, and wherein said blood protein does not specifically bind to said monoclonal antibody;
(b) allowing the monoclonal antibody to bind to the antigen;
(c) determining an amount of the monoclonal antibody bound to the antigen using biolayer interferometry; and
(d) comparing the amount of the monoclonal antibody bound to the antigen to a control threshold to determine an effect of non-specific interactions,
wherein the control threshold is a normalized response to an ideal, dilute, or semi-dilute solution.

### Claim 2 (depends on 1)

The method of claim 1, wherein the blood protein is selected from the group consisting of human serum albumin (HSA), IgG, transferrin, fibrinogen, IgA, α2-macroglobulin, IgM, al-antitrypsin, haptoglobin, α1-acid glycoprotein, apolipoprotein A-1, and apolipoprotein A-11.

### Claim 3 (depends on 2)

The method of claim 2, wherein the blood protein is present at a physiologically relevant concentration.

### Claim 4 (depends on 2)

The method of claim 2, wherein the blood protein is present at a concentration of between about 1 g/L and about 100 g/L.

### Claim 5 (depends on 1)

The method of claim 1, wherein the blood protein is human serum albumin.

### Claim 6 (depends on 1)

The method of claim 1, further comprising determining an amount of binding at two or more concentrations of the blood protein.

### Claim 7 (depends on 1)

The method of claim 1, further comprising determining an amount of binding at two or more pHs to determine a pH dependence of binding.

### Claim 8 (depends on 1)

The method of claim 1, further comprising determining an amount of binding at two or more salt concentrations to determine a salt dependence of binding.

### Claim 9 (depends on 1)

The method of claim 1, wherein the antigen is coupled to the surface of the sensor with a linker.

### Claim 10 (depends on 8)

The method of claim 8, wherein the linker comprises biotin and streptavidin or avidin.
